drugset / Trial / NCT07123545
Autologous Neoantigen-Specific T-Cell Therapy for Advanced Hepatocellular Carcinoma
Phase 1/2
Recruiting
20 enrolled
Zhejiang University
Hangzhou Neoantigen Therapeutics Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
The goal of this open-label, single-arm phase I/II clinical trial is to evaluate the feasibility, safety, and anti-tumor efficacy of the autologous neoantigen-specific T-cell therapy (iNeo-Vac-T01) in patients with advanced hepatocellular carcinoma who have failed second-line or later systemic therapies.
Timeline
- Start
- 2025-08-01
- Primary completion
- 2027-07-31
- Completion
- 2029-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | iNeo-Vac-P01 Personalized Neoantigen Peptide Vaccine | Vaccine | 0.3 mg | Subcutaneous |
| Subject | iNeo-Vac-T01 Personalized T Cell Injection | Cell therapy | 5e+09 cells | Intravenous |
| Subject | iNeo-Vac-T01 Personalized T Cell Injection | Cell therapy | 1e+10 cells | Intravenous |
| Subject | iNeo-Vac-T01 Personalized T Cell Injection | Cell therapy | 5e+10 cells | Intravenous |